Veteran investor Oleg Nodelman joins Galapagos board
Plus: New CEOs at QuantX, Oak Hill, and updates from Every Cure, Mosaic, Anixa and more
Oleg Nodelman joined the board of Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), the Belgian oncology and immunology company led by Chair and CEO Paul Stoffels. After a change in focus and direction when Stoffels joined the company in 2022 in a homecoming of sorts, the company has struggled to find its footing of late, its stock down 27% year-to-date. Nodelman, founder and portfolio manager of Galapagos investor EcoR1 Capital, is a longtime biotech investor who brings deep experience in growing biotechs. He replaces Dan Baker, who stepped down on Oct. 6.
Rare disease company Oak Hill Bio Inc. promoted Josh Distler to CEO and Ike Greenstein to CBO, and hired Sharon Morriss as COO. Distler and Greenstein, both company co-founders, were president and CFO, and VP of corporate development, respectively. Morriss was SVP, clinical development at Lung Therapeutics Inc., now Aileron Therapeutics Inc. (NASDAQ:ALRN). Oak Hill also said Jiaping Gu, Hussein Al-Mossawi and Kim Davis to its board...